Thursday, September 27, 2007
Genetic Disease? Isn't she too Old for that?
Posted by
Steve Murphy MD
at
5:09 PM
2
comments
Labels: gene sherpa, gene tests, genetic discrimination, internal medicine, internist, tangier's disease
Monday, July 16, 2007
Weekend Off, But Genetics Never Rests.
I took the weekend off from posting because I was in the hospital 3 days in a row. It is truly amazing how little you know when you start internship. I am frankly amazed that there aren't more problems during July. The statisticians must have been crazy.
Rule number 1-Don't get elective care in July
Rule number 2-Don't go to a training hospital in July
Rule number 3-Always ask about the medications a nurse gives you
Enough public service.....Back to genomics and personalized medicine.
I was sent an email the other day from a company called Genelex. You may have heard of them. They have been offering pharmacogenomic testing since 2000. Yes that is correct. I thought we should take the time to review what this company offers.
The first tool is called GeneMedRx.
According to the site : GeneMedRx is the first software tool available to prescribers that predicts drug-drug interaction risk based on both cytochrome P450 metabolism and genetic testing. This allows for enhanced understanding of metabolism-based adverse drug interactions or lack of efficacy.
I would say that after reviewing this tool it is a very good resource that should be considered. In addition, a company such as Revolution Health or even an EMR would be smart to snap up a tool such as this. It has over 2000 drugs and metabolites as well as significant links to PubMed. For a demo.
I will continue to review this company throughout the week. They have some very useful and some debatable services as well.
The Sherpa Says: Sorry for the weekend off. I know.........But like C3PO says "Please don't deactivate me" There is alot going on this week and I hope to cover it all. Keep Climbing.
Posted by
Steve Murphy MD
at
6:06 AM
0
comments
Labels: genelex, internal medicine, pharmaceuticals, pharmacogenomics, residency, seattle
Friday, June 22, 2007
Harvard Honoring the Sherpa!

Today I was asked to be on the faculty of Harvard's famous Continuing Medical Education conference in the Genetic Basis of Adult Disease. I am extremely honored to be a part of this distinguished faculty. This year's conference will be held October 12-14th. The last conference topics and website are still up and I am certain the new one will be shortly. I highly recommend it for all physicians looking to become Sherpas or at least to stay up with the breakneck pace of genetic discovery in medicine. Several topics include:
- Genetic Causes of Heart Failure
- Genetics of Lipid Disorders
- Genetics of Cardiovascular Disease
- Genetics of Common Psychiatric Diagnoses
- Genetics, Lung Cancer and Treatment Responses
- Genetics of Gastro-Intestinal Diseases
- Barriers to the collection and use of the Family Health History in Primary Care
So who should attend this great conference?
Internal Medicine Docs
Family Physicians
Genetic Counselors
Registered Nurses
Nurse Practitioners
Physician Assistants
I was at the conference last year and am excited to be behind the podium this year. Please mark your calendars!!!!
Posted by
Steve Murphy MD
at
6:02 PM
1 comments
Labels: CME, Colon cancer, drudge report, francis collins, Harvard, internal medicine, Lung cancer, personalized medicine, scienceroll
Wednesday, May 9, 2007
Mammography at 40
Recently the American College of Physicians (The Organization of Internal Medicine/ACP) released guidelines regarding mammography at 40 years of age. Until now the ACP guidelines were everyone 40 and over gets mammography. There is very little good literature that supports this previous recommendation, yet the American Cancer Society, ASCO, and ACOG still recommend that every woman 40 and above gets a mammo every 1-2 years. The ACP found that in their analysis the conclusion was "Although few women 50 years of age or older have risks from mammography that outweigh the benefits, the evidence suggests that more women 40 to 49 years of age have such risks." After reading the study and looking at the guidelines, they are not that drastic. Key Point Include
- Women 40-49 should have routine risk assessments for breast cancer risk. What is increased risk?
- 2 first degree relatives with breast cancer
- One with breast cancer and a previous breast biopsy(the patient)
- Previous breast cancer
- Previous noncancerous breast gland changes(DCIS, atypical hyperplasia)
- Prior chest irradiation (for cancers/not for a chest xray)
- BRCA1 or 2 mutations or family members with these mutations
- Physicians should inform these 40-49 year old women of the risks and benefits of mammography. What are the risks?
- False positive results (never shown to cause psychiatric problems:anxiety, depression etc.)
- Radiation exposure
- False reassurance from missed tumor
- Clinicians should base their screening mammography decisions on the woman's preference and risk profile.
The Gene Sherpa says: If you are younger than 50 mammography should be a collaborative choice between the physician and the patient. The problem?....When has a physician used a risk assessment tool to evaluate a patient for breast cancer? Sure cancer geneticists do this. But Internists? Sounds like we need some education for the internist, and for the patient. Would you get the mammogram?
Posted by
Steve Murphy MD
at
8:04 AM
0
comments
Labels: ACP, biopsy, BRCA, BRCA1, BRCA2, Breast cancer, gynecology, internal medicine, mammography, obstetrics, oncology, ovarian cancer, prostate cancer, radiation
Wednesday, May 2, 2007
Gene Doping in Athletes
This week in EMBO reports (European Molecular Biology Organization) the dreaded issue of gene doping rears its ugly head. Normally I only report on genetics pertinent to your health. However this raises special interest for me. I was a college athlete and am fascinated by the extremes to which we would go to shave off that 0.5 second. This article raises significant questions about using gene therapy to enhance performance. Where will we stop, what line will be drawn? Gene therapy to cure disease....Why isn't weakness a disease? What about poor vision? We allow athletes to have LASIK, why not gene therapy? The danger is gene overdose. Once introduced into the body we have very poor mechanisms to control expression. But for that extra 0.5 seconds is it worth it? What about for those extra 200 points on the SAT?
The natural extension for these test yourself companies is now treat yourself. Are you a 100lb weakling? What about being predisposed to obesity? Treat yourself. Would you?
Posted by
Steve Murphy MD
at
5:36 PM
0
comments
Labels: athletics, drudgereport, drug testing, gene doping, genetics, genetics and health, internal medicine, LASIK, olympics, pharmacogenomics, sanjaya, SAT
Wednesday, April 18, 2007
Personalized Medicine is coming
I am back! What a fun week in San Diego. I was at a conference for Program Directors (Responsible for training resident physicians) in Internal Medicine. During my absence a few things have come up. But first I want to talk about the conference and how almost all program directors acknowledged that they do not teach genetics in their curriculum. Moreover, several expressed interest in our curriculum. I am so excited that these teachers are now realizing the power of genomic medicine.
That being said.....Appropriate use of the genome brings great results. Misuse and blatant promotion such as that done by a direct to consumer testing center in San Francisco (I will not say their name) will only lead to sullying of the geneticists' reputations.
On Genetics and Health there is a post which lead me to a website that was promoting risk factor testing for diabetes. Like any other path I will lead you through, there is good, bad, and unknown. First the good.
Diabetes is an awful disease and the longer it is untreated the worse the outcomes. So naturally I am excited about being able to diagnose it quicker. BUT this test does not diagnose, it only shows increased risk.
Here comes the bad.
In fact, the risk of carrying this gene polymorphism is not even half as much as having a sibling with Type 2 diabetes. Why would a company promote this test rather than promote taking a family history? The answer is simple, because they make MONEY off the test or interpretation and not off taking a family history and counseling in person. I have no respect for that. In fact, people will be amazed to know that this company makes all of its profit from marking up test costs or non face to face services, and serving as an "educational" resource. What education leaves out that the best screening test for hemochromatosis is iron studies? Shame on them.
Lastly, the unknown.
Now that I know this risk, how do I use it clinically. There is no study showing that metformin or a PPAR gamma here will prevent the onset of diabetes in this risk group. What I am saying is....before we go down this road 3 things need to be done
- A 3 generation family history
- Research on prevention in this high risk group
- Companies looking to make a quick buck off of you on testing without clinical utility need to be punished. Or at least I can lead you away from that confusing and dangerous path.
If you do wish to do in home testing without the help of a TRAINED genetic specialist who examines you and takes a full family history, then you risk the difficulty of test interpretation, appropriate follow up, and possibly improper care as a result. I hope you choose wisely.
Posted by
Steve Murphy MD
at
6:49 PM
0
comments
Labels: APDIM, diabetes, DNA, DNA direct, gene sherpa, gene tests, genetics and health, HRT, human genome project, internal medicine, menopause, personal genome, pharmacogenomics, San Diego

